337 related articles for article (PubMed ID: 23708174)
1. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
[TBL] [Abstract][Full Text] [Related]
2. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
[TBL] [Abstract][Full Text] [Related]
3. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
[TBL] [Abstract][Full Text] [Related]
4. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
Glynn RJ; Koenig W; Nordestgaard BG; Shepherd J; Ridker PM
Ann Intern Med; 2010 Apr; 152(8):488-96, W174. PubMed ID: 20404379
[TBL] [Abstract][Full Text] [Related]
6. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
[TBL] [Abstract][Full Text] [Related]
7. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; MacFadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
N Engl J Med; 2008 Nov; 359(21):2195-207. PubMed ID: 18997196
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
Carter NJ
Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
[TBL] [Abstract][Full Text] [Related]
10. Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.
Hu M; Tomlinson B
Atherosclerosis; 2012 Aug; 223(2):427-32. PubMed ID: 22749334
[TBL] [Abstract][Full Text] [Related]
11. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
[TBL] [Abstract][Full Text] [Related]
12. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.
García-Rodríguez LA; Massó-González EL; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):943-52. PubMed ID: 18425988
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
Fellström BC; Jardine AG; Schmieder RE; Holdaas H; Bannister K; Beutler J; Chae DW; Chevaile A; Cobbe SM; Grönhagen-Riska C; De Lima JJ; Lins R; Mayer G; McMahon AW; Parving HH; Remuzzi G; Samuelsson O; Sonkodi S; Sci D; Süleymanlar G; Tsakiris D; Tesar V; Todorov V; Wiecek A; Wüthrich RP; Gottlow M; Johnsson E; Zannad F;
N Engl J Med; 2009 Apr; 360(14):1395-407. PubMed ID: 19332456
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.
Chu AY; Guilianini F; Barratt BJ; Nyberg F; Chasman DI; Ridker PM
Circ Cardiovasc Genet; 2012 Feb; 5(1):58-65. PubMed ID: 22230323
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
Hsia J; MacFadyen JG; Monyak J; Ridker PM
J Am Coll Cardiol; 2011 Apr; 57(16):1666-75. PubMed ID: 21492764
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
Ridker PM; Pradhan A; MacFadyen JG; Libby P; Glynn RJ
Lancet; 2012 Aug; 380(9841):565-71. PubMed ID: 22883507
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
Glynn RJ; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; MacFadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Ridker PM
N Engl J Med; 2009 Apr; 360(18):1851-61. PubMed ID: 19329822
[TBL] [Abstract][Full Text] [Related]
20. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
